<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04703075</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00252979</org_study_id>
    <secondary_id>U01AI152961</secondary_id>
    <nct_id>NCT04703075</nct_id>
  </id_info>
  <brief_title>Treatment Success and Safety of 4 Weeks of Daily Rifapentine and Isoniazid (1HP) vs. 12 Weeks of Weekly Rifapentine and Isoniazid (3HP) for Prevention of Tuberculosis in HIV-uninfected Individuals (1v3HP for TPT in HIV-uninfected Individuals)</brief_title>
  <official_title>Treatment Success and Safety of 4 Weeks of Daily Rifapentine and Isoniazid (1HP) vs. 12 Weeks of Weekly Rifapentine and Isoniazid (3HP) for Prevention of Tuberculosis in HIV-uninfected Individuals (1v3HP for TPT in HIV-uninfected Individuals)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare treatment success (adherence and completion of treatment) and safety of 1HP with&#xD;
      3HP in HIV-uninfected adults and adolescents at increased risk of TB.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tuberculosis (TB) is the leading infectious killer globally and a major cause of illness and&#xD;
      suffering. The World Health Organization has prioritized TB preventive therapy (TPT) for&#xD;
      people with latent TB infection (LTBI) as a key strategy for controlling the epidemic.&#xD;
      Prevention of TB with isoniazid preventive therapy (IPT) is effective and reduces morbidity&#xD;
      and mortality, and has been the mainstay of TB prevention for decades. But for an&#xD;
      intervention with an excellent evidence of efficacy, global uptake has been abysmal.&#xD;
      Completion rates for IPT when it is administered are poor (Gillespie 2008; Durovni 2010),&#xD;
      with a large proportion of patients unable to complete treatment (McClintock 2017; Sterling&#xD;
      2011). While uptake is influenced by a variety of factors, a critical element has been the&#xD;
      duration of IPT, with adherence falling sharply over time in clinical trials and practice.&#xD;
      Shorter course regimens have a much higher completion rate and are more acceptable to&#xD;
      patients, clinicians, and programs.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">September 2024</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Arm A (n=250): Experimental arm. Rifapentine 600 mg daily and isoniazid 300 mg daily for 4 weeks.&#xD;
Arm B (n=250): Control arm. Rifapentine 900 mg and isoniazid 900 mg weekly for 12 weeks.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants who complete treatment with &gt;90% adherence</measure>
    <time_frame>2 years</time_frame>
    <description>To compare treatment success (completion of treatment with &gt;90% adherence) of 1HP with 3HP in HIV-uninfected adults and adolescents at increased risk of TB.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>Rifapentine 600 mg and Isoniazid 300 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Rifapentine 600 mg daily and isoniazid (INH) 300 mg daily for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rifapentine 900 mg and Isoniazid 900 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive Rifapentine 900 mg and isoniazid 900 mg weekly for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifapentine 600 mg and INH 300 mg</intervention_name>
    <description>Participants will receive Rifapentine 600 mg and INH 300 mg</description>
    <arm_group_label>Rifapentine 600 mg and Isoniazid 300 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifapentine 900 mg and INH 900 mg</intervention_name>
    <description>Participants will receive Rifapentine 900 mg and INH 900mg</description>
    <arm_group_label>Rifapentine 900 mg and Isoniazid 900 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Positive tuberculin skin test or interferon-gamma release assay (IGRA) test and&#xD;
&#xD;
          -  Household contact of an infectious TB case within previous 90 days, defined as&#xD;
             sleeping at least once in a residence with a person diagnosed with pulmonary TB, or&#xD;
&#xD;
          -  Documented conversion of Tuberculin skin test (TST)/IGRA from negative to positive&#xD;
             within 2 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Documented HIV infection&#xD;
&#xD;
          -  Evidence of active tuberculosis on clinical exam or chest x-ray&#xD;
&#xD;
          -  Known intolerance of any study drug&#xD;
&#xD;
          -  Treatment for active or latent TB in the past for more than 14 days&#xD;
&#xD;
          -  Known close contact to someone with INH or rifampin resistant TB&#xD;
&#xD;
          -  Active liver disease or Aspartate aminotransferase(AST)/Alanine transaminase (ALT) &gt;3&#xD;
             times upper limit of normal (ULN)&#xD;
&#xD;
          -  Neutropenia (ANC &lt;1000)&#xD;
&#xD;
          -  Peripheral neuropathy &gt;Grade 1 by DAIDS Grading Table&#xD;
&#xD;
          -  Pregnant or breastfeeding. Women of childbearing potential must agree to use&#xD;
             non-hormonal contraception during study treatment.&#xD;
&#xD;
          -  Weight &lt;40 kg&#xD;
&#xD;
          -  At risk of poor outcome based on clinical judgment and discretion of investigator.&#xD;
&#xD;
          -  Required use of a prohibited medication with a serious drug-drug interaction with&#xD;
             rifamycins or isoniazid.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Chaisson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Grace Barnes, MPH</last_name>
    <phone>4438545884</phone>
    <email>glbarnes@jhmi.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Richard Chaisson, MD</last_name>
    <phone>4109551755</phone>
    <email>rchaiss@jhmi.edu</email>
  </overall_contact_backup>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>January 7, 2021</study_first_submitted>
  <study_first_submitted_qc>January 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 11, 2021</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifapentine</mesh_term>
    <mesh_term>Rifampin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

